Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone713-300-5160
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions
What is Moleculin Biotech's stock symbol?
Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."
How were Moleculin Biotech's earnings last quarter?
Moleculin Biotech Inc (NASDAQ:MBRX) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.14) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.05. View Moleculin Biotech's Earnings History.
When is Moleculin Biotech's next earnings date?
What price target have analysts set for MBRX?
2 Wall Street analysts have issued twelve-month price targets for Moleculin Biotech's shares. Their forecasts range from $3.00 to $8.00. On average, they expect Moleculin Biotech's stock price to reach $5.50 in the next year. This suggests a possible upside of 366.1% from the stock's current price. View Analyst Price Targets for Moleculin Biotech.
What is the consensus analysts' recommendation for Moleculin Biotech?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Moleculin Biotech.
What are Wall Street analysts saying about Moleculin Biotech stock?
Here are some recent quotes from research analysts about Moleculin Biotech stock:
- 1. Maxim Group analysts commented, "Moleculin reported YE18 with a net loss of ($11.9M) and ended the period with ~$7M in cash, runway into 3Q19. The company also has $18M remaining on an equity line. Management continued to execute in 2018 and position its two lead programs (Annamycin and the STAT3 candidates) to reach data points in 2019, which should if positive unlock value for MBRX shareholders. Important in our view is to focus on why these assets are differentiated in the oncology space and how that could translate into a higher probability of success in the clinic. We review in more detail below." (2/26/2019)
- 2. According to Zacks Investment Research, "Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. " (2/14/2019)
Has Moleculin Biotech been receiving favorable news coverage?
Media headlines about MBRX stock have been trending somewhat positive on Saturday, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Moleculin Biotech earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Moleculin Biotech.
Who are some of Moleculin Biotech's key competitors?
Some companies that are related to Moleculin Biotech include Ocular Therapeutix (OCUL), Marinus Pharmaceuticals (MRNS), Aeglea Bio Therapeutics (AGLE), Five Prime Therapeutics (FPRX), MannKind (MNKD), Mersana Therapeutics (MRSN), Chiasma (CHMA), Cerecor (CERC), Edge Therapeutics (EDGE), Affimed (AFMD), Harrow Health (HROW), Kala Pharmaceuticals (KALA), American Brivision (Holding) (ABVC), Abeona Therapeutics (ABEO) and Chimerix (CMRX).
What other stocks do shareholders of Moleculin Biotech own?
Who are Moleculin Biotech's key executives?
Moleculin Biotech's management team includes the folowing people:
- Mr. Walter V. Klemp, Founder, Chairman, Pres & CEO (Age 59)
- Mr. Jonathan P. Foster, CFO & Exec. VP (Age 55)
- Dr. Donald H. Picker, Chief Scientific Officer (Age 73)
- Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory Board
- Dr. Robert C. Shepard, Chief Medical Officer (Age 67)
How do I buy shares of Moleculin Biotech?
Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Moleculin Biotech's stock price today?
One share of MBRX stock can currently be purchased for approximately $1.18.
How big of a company is Moleculin Biotech?
Moleculin Biotech has a market capitalization of $53.32 million. The company earns $-11,880,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Moleculin Biotech employs 9 workers across the globe.View Additional Information About Moleculin Biotech.
What is Moleculin Biotech's official website?
How can I contact Moleculin Biotech?
Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77054. The company can be reached via phone at 713-300-5160.
MarketBeat Community Rating for Moleculin Biotech (NASDAQ MBRX)
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe MBRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
